Komori
Human Metabolome Technologies (6090) · InitiativeAdvanced

Introduction of a Performance-Conditioned Deferred-Delivery Restricted Stock Compensation Plan

First written in FY2021. 7 of 9 entries say "Advanced", first in FY2022. Latest entry: 2026-10-16.

9entries
6years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2021AdvancedFY2022 – FY20242021: 120212022: 220222023: 120232024: 120242025: 020252026: 42026
Same theme, other companies
Performance-based executive and employee compensation schemeA theme 405 companies write about · 0 as a headwind · 397 as a tailwind

The whole theme swung hardest in 2024: 13 of 118 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 191 companies compared. The sentences above are computed from all 191.Comparing 200 of the theme's 418 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「The disposal of 7,926 treasury shares involved the disposal, on 17 October 2025, of 7,926 treasury shares to grant restricted stock to 2 directors, excluding directors who are Audit and Supervisory Committee members.」

    Under the performance-linked, post-delivery restricted stock compensation plan, 7,926 treasury shares were disposed of for 2 directors.
  2. 2026-08-07OtherGovernance

    「Under this program, the Board of Directors will determine the eligible employees, who will receive an issue or disposal of the company’s common shares (the “shares allocated under this program”).」

    Because its eligible recipients and purpose differ from the existing performance-based, post-delivery restricted stock compensation for directors, this was not treated as progress in the same thread.
  3. FY2024AdvancedAnnual report

    「As performance-linked, post-delivery restricted stock compensation, we issued 8,558 new shares through an in-kind contribution, with 20 October 2023 as the payment date.」

    For the performance-linked, post-delivery restricted stock compensation plan, the issuance of 8,558 new shares for 2 directors was completed.
  4. FY2024-Q1AdvancedAnnual report

    「As performance-linked, post-delivery restricted stock compensation, we issued 8,558 new shares through an in-kind contribution, with 20 October 2023 as the payment date.」

    For the performance-linked, post-delivery restricted stock compensation plan, the issuance and payment for 8,558 new shares for 2 directors was completed.
  5. FY2023-Q1AdvancedAnnual report

    「Upon completion of payment for the issuance of new shares as performance-linked, post-delivery restricted stock compensation, with 21 October 2022 as the payment date, the number of issued shares increased by 6,875 shares, capital increased by ¥3.059 million, and capital surplus increased by ¥3.059 million.」

    For the performance-linked, post-delivery restricted stock compensation plan, the issuance and payment for 6,875 new shares for 2 directors was completed on 21 October 2022.
  6. FY2022AdvancedAnnual report

    「Non-monetary compensation represents the amount recognized as an expense for the current fiscal year in respect of the estimated compensation under the performance-linked, post-delivery restricted stock compensation plan.」

    The performance-linked, post-delivery restricted stock compensation plan introduced in the previous fiscal year entered the operational stage, and ¥6.120 million was recognized as non-monetary compensation expense for the current fiscal year.
  7. FY2021First statedAnnual report

    「For the following fiscal year, the fiscal year ending June 2022, executive compensation will be revised pursuant to a resolution of the 18th Annual General Meeting of Shareholders and will consist of this stock-based compensation in addition to fixed basic compensation and performance-based compensation.」

    From the fiscal year ending June 2022, the company introduced a performance-linked, post-delivery restricted stock compensation plan for directors, excluding outside directors and directors who are Audit and Supervisory Committee members. Compensation is capped at ¥100 million per year, and the total number of shares is capped at 40,000 shares per year.
Moved together

"Capital investment to expand analytical capabilities and accelerate research and development" moved the same way as this thread, in the same document, in 4 of its 9 moves.

433332★123456
  1. ★This thread
  2. 1Capital investment to expand analytical capabilities and accelerate research and development4×
  3. 2Development of a New Service in the Metabolome Analysis Business3×
  4. 3Policy of prioritizing retained earnings and considering future dividends3×
  5. 4Healthcare Solutions Business: ¥100 million in sales and segment profitability in five years3×
  6. 5Launch of a Comprehensive Support Service for Functional Materials Development and Establishment of a Business Foundation3×
  7. 6Proactive Talent Acquisition and Organizational Revitalization2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Human Metabolome Technologies yet. It last moved in the Share Issuance and Disposal of 2026-10-16: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Introduction of a Performance-Conditioned Deferred-Delivery Restricted Stock Compensation Plan | Human Metabolome Technologies,Inc. (6090) | Komori